80 studies found for:    Open Studies | "Epstein-Barr Virus Infections"
Show Display Options
Rank Status Study
21 Recruiting A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
Conditions: Diffuse Large B-cell Lymphoma;   Follicular Lymphoma;   Burkitt Lymphoma
Intervention: Drug: Alisertib
22 Recruiting Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Conditions: Non-Hodgkin Lymphoma;   Burkitt's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Waldenstrom Macroglobulinemia
Intervention: Drug: ADCT-402
23 Not yet recruiting Allo HSCT Using RIC for Hematological Diseases
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
Interventions: Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
24 Recruiting Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   B Lymphoblastic Leukemia/Lymphoma;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Burkitt Leukemia;   Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3 Follicular Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Mycosis Fungoides;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Nodal Marginal Zone Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Post-Transplant Lymphoproliferative Disorder;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Primary Effusion Lymphoma;   Sezary Syndrome;   Splenic Marginal Zone Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   Systemic Anaplastic Large Cell Lymphoma;   T Lymphoblastic Leukemia/Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Dietary Supplement: Salvia hispanica Seed
25 Recruiting Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults
Condition: Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia
Intervention:
26 Recruiting Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Condition: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Intervention: Biological: CART22 cells
27 Recruiting Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Mediastinal Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
28 Recruiting Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: JCAR015 (CD19-targeted CAR T cells)
29 Not yet recruiting Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Conditions: Adult Burkitt Lymphoma;   Adult Diffuse Large B-Cell Lymphoma;   CD20-Positive Neoplastic Cells Present;   Indolent Adult Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;   Radiation: indium In 111-DOTA-biotin;   Radiation: yttrium Y 90 DOTA-biotin;   Drug: Clearing Agent;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
30 Not yet recruiting Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
31 Not yet recruiting The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
Conditions: Infectious Mononucleosis;   Splenomegaly
Intervention: Device: Point-of-care ultrasound
32 Recruiting CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
Conditions: Acute Lymphoblastic Leukemia;   Burkitt Lymphoma
Interventions: Procedure: Leukapheresis;   Drug: Lymphodepletion with fludarabine;   Drug: Lymphodepletion with cyclophosphamide;   Biological: CD19 CAR T-cells
33 Not yet recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Conditions: Activated B-Cell-Like Diffuse Large B-Cell Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Placebo
34 Recruiting Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL
Condition: Lymphoblastic Leukemia, Acute, Childhood
Intervention: Genetic: Single dose of CTL019
35 Recruiting Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Burkitt's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Waldenstrom's Macroglobulinaemia;   Lymphoma,T-cell Cutaneous;   Lymphoma, T-Cell, Peripheral
Intervention: Drug: ADCT-301
36 Recruiting Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Conditions: Non-Hodgkin Lymphoma;   Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   Primary Mediastinal B-cell Lymphoma;   CD20+ Lymphoblastic Lymphoma;   Follicular Lymphoma, Grade III
Interventions: Drug: Obinutuzumab;   Drug: Liposomal ARA-C;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide
37 Recruiting Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Conditions: AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large B-cell Lymphoma;   AIDS-Related Plasmablastic Lymphoma;   AIDS-Related Primary Effusion Lymphoma;   HIV Infection
Interventions: Drug: Prednisone;   Biological: Rituximab;   Drug: Etoposide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
38 Not yet recruiting Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: rituximab;   Drug: lenalidomide;   Drug: romidepsin;   Other: laboratory biomarker analysis
39 Recruiting Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Conditions: B-cell Acute Lymphoblastic Leukemia;   Relapsed B-cell Acute Lymphoblastic Leukemia;   Refractory B-cell Acute Lymphoblastic Leukemia
Intervention: Biological: CTL019 T-cells
40 Recruiting Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)
Condition: Leukemia
Interventions: Drug: Ofatumumab;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Behavioral: Phone Calls

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years